Last reviewed · How we verify
NCT03065374
Treatment for Clostridium-difficile Infection With IMM529
Phase 1, PHASE2 trial testing IMM-529 in Clostridium Difficile Infection in 9 participants. Terminated before completion.
7 November 2019
Quick facts
| Lead sponsor | Immuron Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 1 September 2017 |
| Primary completion | 7 November 2019 |
| Estimated completion | 7 November 2019 |
| Sites | 2 locations across Israel |
Drugs / interventions tested
- IMM-529 — full drug profile →
- Placebo
Conditions studied
- Clostridium Difficile Infection — all drugs for Clostridium Difficile Infection →
- Clostridium Difficile Infection Recurrence — all drugs for Clostridium Difficile Infection Recurrence →
Sponsor
Immuron Ltd. — full company profile →
Who can join
Adults 18 to 99, any sex, with Clostridium Difficile Infection or Clostridium Difficile Infection Recurrence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the safety and tolerability of IMM-529 together with standard of care (SOC) in patients with Clostridium-difficile Infection.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.
Dieterle MG, Rao K, Young VB. · · 2019 · cited 44× · PMID 30238983 · DOI 10.1111/nyas.13958 -
Application of Antibody-Mediated Therapy for Treatment and Prevention of <i>Clostridium difficile</i> Infection.
Förster B, Chung PK, Crobach MJT, Kuijper EJ. · · 2018 · cited 5× · PMID 29988597 · DOI 10.3389/fmicb.2018.01382
Verify or expand the search:
- PubMed search for NCT03065374
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Clostridium Difficile Infection
Currently open trials in the same condition.
- NCT07221370 — Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients · Phase 2, PHASE3 · recruiting
- NCT06703918 — Study on Clostridium Difficile Infection in Infants · recruiting
- NCT04305769 — Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) · Phase 2 · recruiting
- NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation · NA · recruiting
- NCT03562741 — Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile · NA · recruiting
Other Immuron Ltd. trials
Trials by the same sponsor.
- NCT05933525 — Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03065374 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Immuron Ltd.
- Last refreshed: 26 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03065374.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing